Bosentan, an Endothelin Antagonist, Augments Hepatic Graft Function by Reducing Graft Circulatory Impairment Following Ischemia/Reperfusion Injury

Journal of Gastrointestinal Surgery

Volumn 5, Issue 3, 2001, Pages 322-329

  Ricciardi, Rocco ^a   Schafer, Bradley K ^a   Shah, Shimul A ^a   Quarfordt, Steven H ^a   Banner, Barbara F ^a   Wheeler, Suzanne M ^a   Donohue, Susan E ^a   Meyers, William C ^a   Chari, Ravi S ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Blood flow; Endothelin; Function; Ischemia; Liver; Reperfusion

Indexed keywords

ANTIHYPERTENSIVE AGENT; BOSENTAN; ENDOTHELIN RECEPTOR; SULFONAMIDE;

ANIMAL; ARTICLE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GRAFT OCCLUSION; GRAFT SURVIVAL; LIVER; LIVER TRANSPLANTATION; REPERFUSION INJURY; SWINE; VASCULARIZATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GRAFT OCCLUSION, VASCULAR; GRAFT SURVIVAL; LIVER; LIVER TRANSPLANTATION; RECEPTORS, ENDOTHELIN; REPERFUSION INJURY; SULFONAMIDES; SWINE;

EID: 0035348775     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1091-255X(01)80055-X     Document Type: Article

References (27)

1. Clemens MG, McDonagh PF, Chaudry IH, Baue AE. Hepatic microcirculatory failure after ischemia reperfusion: Improvement with ATP-MgCL2 treatment. Am J Physiol 1985;248: H804-H811.
2. Ricciardi R, Foley DP, Quarfordt SH, et al. Cold ischemia affects regional hepatic tissue perfusion [abstr], Hepatology 1999;30:223A.
3. Koo A, Komatsu H, Tao G, Inoue M, Guth PH, Kaplowitz N. Contribution of no-reflow phenomenon to hepatic injury after ischemia-reperfusion: Evidence for a role for superoxide anion. Hepatology 1992;15:507-514.
4. Lautt WW. The 1995 Ciba-Geigy Award Lecture. Intrinsic regulation of hepatic blood flow. Can J Physiol Pharmacol 1996;74:223-233.
5. Ricciardi R, Foley DP, Quarfordt SH, et al. Variables predict ex-vivo support organ function (submitted for publication).
6. Wilhelm SM, Simonson MS, Robinson AV, Stowe NT, Schulak JA. Cold ischemia induces endothelin gene upregulation in the preserved kidney. J Surg Res 1999;85:101-108.
7. Kawamura E, Yamanaka N, Okamoto E, Tomoda F, Furukawa K. Response of plasma and tissue endothelin-1 to liver ischemia and its implication in ischemia reperfusion injury. Hepatology 1995;21:1138-1143.
8. Nakamura S, Nishiyama R, Serizawa A, et al. Hepatic release of endothelin-1 after warm ischemia. Transplantation 1995;59: 679-684.
9. Pannen BH, Al-Adili F, Bauer M, Clemens MG, Geiger KK. Role of endothelins and nitric oxide in hepatic reperfusion injury in the rat. Hepatology 1998;27:755-764.
10. Foley DP, Vittimberga FJ, Quarfordt SH, et al. Biliary secretion of extracorporeal porcine livers with single and dual vessel perfusion. Transplantation 1999;68:362-368.
11. Southard JH, Beizer FO. Organ preservation. Annu Rev Med 1995;46:235-247.
12. Iskitt AB, Sungur A, Gedikoglu G, Oguz Guc M. The effects of bosentan, aminoguanidine and L-canavanine on mesenteric blood flow, spleen, and liver in endotoxaemic mice. Eur J Pharmacol 1999;379:73-80.
13. B receptor antagonist, in portal hypertensive rats. Hepatology 1998;28: 655-659.
14. Koeppel TA, Kraus T, Thies JC, Gebhard MM, Otto G, Post S. Effects of mixed ETA and ETB receptor antagonist (Ro-47-0203) on hepatic microcirculation after warm ischemia. Dig Dis Sci 1997;42:1316-1321.
15. Asada M, Galambos JT. Sorbitol dehydrogenase and hepatocellular injury: An experimental and clinical study. Gastroenterology 1963;44:578-587.
16. Wiesner IS, Rawnsley HM, Brooks FP, Senior JR. Sorbitol dehydrogenase in the diagnosis of liver disease. Am J Dig Dis 1965;10:147-151.
17. Jenkins SJ, Green SA, Clark PA. Clinical chemistry reference values of normal domestic animals in various age groups - as determined on the ABA-100. Cornell Vet 1982;72:403-415.
18. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
19. Randall MD. Vascular activities of the endothelins. Pharmacol Ther 1991;50:73-93.
20. Rakugi H, Tabuchi Y, Nakamura M, et al. Evidence for endothelin-1 release from resistance vessels of rats in response to hypoxia. Biochem Biophys Res Commun 1990;169:973-977.
21. Moreland S. Endothelin receptor antagonists: A brief review. Can J Physiol Pharmacol 1994;72:1469-1471.
22. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994; 270:228-235.
23. Williamson DJ, Wallman LL, Jones R, et al. Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 2000;102: 411-418.
24. Sustch G, Bertel O, Richenbacher P, et al. Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins. Am J Cardiol 2000;85:973-976.
25. Kitayama Y, Yamanaka N, Kawamura E, Kuroda N, Okamoto E. Hepatoprotective effect of the endothelin receptor antagonist TAK-044 against ischemia-reperfusion injury in the canine liver. Hepatology 1997;27:1652-1660.
26. Yamanaka N, Takaya Y, Oriyama T, et al. Hepatoprotective effect of a nonselective endothelin receptor antagonist (TAK-044) in the transplanted liver. J Surg Res 1997;70:156-160.
27. Urakami A, Todo S, Zhu Y, et al. Attenuation of ischemic liver injury by monoclonal anti-endothelin antibody, AwETN40. J Am Coll Surg 1997;185:358-364.